Dominic Marasco - 14 May 2025 Form 4 Insider Report for MANNKIND CORP (MNKD)

Role: Pres, Endocrine Business Unit
Signature: /s/ Dominic Marasco
Issuer symbol: MNKD
Transactions as of: 14 May 2025
Net transactions value: +$99,996
Form type: 4
Filing time: 16 May 2025, 18:20:27 UTC
Previous filing: 13 Feb 2025
Next filing: 25 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Marasco Dominic	Pres, Endocrine Business Unit	1 CASPER STREET, DANBURY	/s/ Dominic Marasco	16 May 2025	0002053897

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNKD	Common Stock, $0.01 Par Value	Award	$0	+59,500	+24%	$0.000000	311,500	14 May 2025	Direct	F1
transaction	MNKD	Common Stock, $0.01 Par Value	Award	$99,996	+21,929	+7%	$4.56	333,429	14 May 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MNKD	Performance Restricted Stock Unit	Award	$0	+72,500		$0.000000	72,500	14 May 2025	Common Stock, $0.01 Par Value	72,500		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F2	The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on May 14, 2025.
F3	Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
F4	The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.